BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holubová M, Špolcová A, Demianová Z, Sýkora D, Fehrentz JA, Martinez J, Štofková A, Jurčovičová J, Drápalová J, Lacinová Z, Haluzík M, Železná B, Maletínská L. Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice. Physiol Res. [DOI: 10.33549/physiolres.932488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Holubová M, Nagelová V, Lacinová Z, Haluzík M, Sýkora D, Moulin A, Blayo A, Fehrentz J, Martinez J, Stofkova A, Jurčovičová J, Železná B, Maletínská L. Triazole GHS-R1a antagonists JMV4208 and JMV3002 attenuate food intake, body weight, and adipose tissue mass in mice. Molecular and Cellular Endocrinology 2014;393:120-8. [DOI: 10.1016/j.mce.2014.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Maletínská L, Nagelová V, Tichá A, Zemenová J, Pirník Z, Holubová M, Špolcová A, Mikulášková B, Blechová M, Sýkora D, Lacinová Z, Haluzík M, Železná B, Kuneš J. Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int J Obes 2015;39:986-93. [DOI: 10.1038/ijo.2015.28] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
3 Mikulášková B, Maletínská L, Zicha J, Kuneš J. The role of food intake regulating peptides in cardiovascular regulation. Molecular and Cellular Endocrinology 2016;436:78-92. [DOI: 10.1016/j.mce.2016.07.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
4 Santos JMO, Costa AC, Dias TR, Satari S, Costa E Silva MP, da Costa RMG, Medeiros R. Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates. Pharmaceuticals (Basel) 2021;14:1084. [PMID: 34832866 DOI: 10.3390/ph14111084] [Reference Citation Analysis]
5 M'Kadmi C, Leyris JP, Onfroy L, Galés C, Saulière A, Gagne D, Damian M, Mary S, Maingot M, Denoyelle S, Verdié P, Fehrentz JA, Martinez J, Banères JL, Marie J. Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling. J Biol Chem 2015;290:27021-39. [PMID: 26363071 DOI: 10.1074/jbc.M115.659250] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 8.1] [Reference Citation Analysis]
6 Spolcová A, Holubová M, Mikulášková B, Nagelová V, Stofková A, Lacinová Z, Jurčovičová J, Haluzík M, Maletínská L, Zelezná B. Changes in FGF21 serum concentrations and liver mRNA expression in an experimental model of complete lipodystrophy and insulin-resistant diabetes. Physiol Res 2014;63:483-90. [PMID: 24908095 DOI: 10.33549/physiolres.932714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zollers B, Huebner M, Armintrout G, Rausch-derra LC, Rhodes L. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite. J vet Pharmacol Therap 2017;40:248-55. [DOI: 10.1111/jvp.12358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 Buckinx A, Pierre A, Van Den Herrewegen Y, Guenther E, Gerlach M, Van Laethem G, Kooijman R, De Bundel D, Smolders I. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol 2021;28:3100-12. [PMID: 34157194 DOI: 10.1111/ene.14992] [Reference Citation Analysis]
9 Pastor-Cavada E, Pardo LM, Kandil D, Torres-Fuentes C, Clarke SL, Shaban H, McGlacken GP, Schellekens H. A Novel Non-Peptidic Agonist of the Ghrelin Receptor with Orexigenic Activity In vivo. Sci Rep 2016;6:36456. [PMID: 27819353 DOI: 10.1038/srep36456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]